PFE Revenue
Revenue at Pfizer fell to $62.6B in fiscal 2025, from $63.6B in 2024.
Total revenues as filed (us-gaap fallback chain; for financials, net revenue or net interest income). Source tag recorded per name.
SOURCE: us-gaap:Revenues · EDGAR CompanyFacts · CIK 78003 · EDGAR ↗ · FY2021–FY2025 · ANNUAL
History AS FILED · DERIVATION SHOWN WHERE DERIVED
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2025 | $62.6B | $-1.0B |
| FY2024 | $63.6B | +$4.1B |
| FY2023 | $59.6B | $-41.6B |
| FY2022 | $101.2B | +$19.9B |
| FY2021 | $81.3B | — |
Cross-checks touching this measure FROM THE FILING REVIEW
◐ PARTLYinternational revenue mix
The quoted figures do not map one-for-one onto a filed line on this page; carried as partly supported.
FY2025 10-K · FULL RECONCILIATION →◐ PARTLYtotal revenue decline
4 of 6 quoted figures reconcile ($1.0 billion against total revenues; $62.6 billion against total revenues; $63.6 billion against total revenues); $1.3 billion, $247 million does not map to a filed line on this page — carried as partly supported. The source sentence carries qualifiers beyond the 40-word quote limit; carried as partly supported.
FY2025 10-K · FULL RECONCILIATION →✓ CLEANReceivables pace
Days sales outstanding moved +3.5 days — inside the ±7-day watch threshold.
FY2025 10-K · FULL RECONCILIATION →✓ CLEANInventory vs revenue pace
Inventory moved -1.8%, revenue -1.6% (gap -0.2pp). The flag tests inventory OUTRUNNING revenue by more than 7pp.
FY2025 10-K · FULL RECONCILIATION →More SAME DATA, OTHER VIEWS
Revenue across coverage → · PFE company view →
Net income · Operating cash flow · Free cash flow · Capital expenditure · Cash & equivalents · Total assets · Shareholders' equity · Total debt · Return on equity · Days sales outstanding
Not investment advice. Every figure on this page is an XBRL fact from the issuer's own SEC filings or an arithmetic over such facts with the method shown. No forecast is made; no posture is expressed.